Press Release: KaloCyte CEO to Present at NIH Innovation Conference and Life Sciences Summit

KaloCyte CEO to Present at NIH Innovation Conference and Life Sciences Summit
Company Continues Momentum Following Recent Relocation to Baltimore

BALTIMORE, Md., November 4, 2019KaloCyte[1], Inc., a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, has been selected to present this week at both the National Institutes of Health (NIH) Innovation Conference (NIC) and the Life Sciences Summit (LSS) in New York City.

“We’re honored to be selected to both gain valuable feedback from the mentors at NIC, and to share our story with potential partners and investors at the LSS,” said Elaine Haynes, president and CEO of KaloCyte. “Attendees of both sessions will learn about ErythroMer, our bio-inspired artificial, freeze-dried red blood cell, that has the potential to save countless lives both on and off the battlefield.”

During the half-day NIC, Haynes will present to NIH representatives, life science investors, and industry executives who will serve as mentors, providing her with live feedback in preparation for the LSS. The Summit is an early-stage investor and business development conference for emerging companies and academic innovators. The objective of the meeting is to connect emerging companies with early-stage investors, business development professionals, and medical research foundations. The KaloCyte presentation at the LSS is Thursday, Nov. 7 at 2:30 p.m. at The Convene in the Soho Hub.

KaloCyte recently moved its headquarters from St. Louis to Baltimore, becoming a University of Maryland BioPark[2] affiliate and joining the vibrant life science ecosystem in Baltimore and Maryland. The relocation also positioned the Company closer to the NIH National Heart, Lung, and Blood Institute’s (NHLBI) Small Business Program and the U.S. Department of Defense (DoD) Army Combat Casualty Care Research Program, both of which are KaloCyte key stakeholders and funders.

1 2 3